A Double Blind, Placebo-controlled First Time in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK3036656 in Healthy Adult Volunteers

Trial Profile

A Double Blind, Placebo-controlled First Time in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK3036656 in Healthy Adult Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs GSK 3036656 (Primary)
  • Indications Tuberculosis
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 08 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 03 Aug 2017 Planned End Date changed from 25 Jul 2017 to 4 Aug 2017.
    • 03 Aug 2017 Planned primary completion date changed from 25 Jul 2017 to 4 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top